Literature DB >> 29268497

Heparin versus bivalirudin for percutaneous coronary intervention: has the debate come to an end?

Islam Y Elgendy1, Davide Capodanno2.   

Abstract

Entities:  

Year:  2017        PMID： 29268497      PMCID： PMC5721029          DOI： 10.21037/jtd.2017.10.23

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  23 in total

1.  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.

Authors:  Adnan Kastrati; Franz-Josef Neumann; Stefanie Schulz; Steffen Massberg; Robert A Byrne; Miroslaw Ferenc; Karl-Ludwig Laugwitz; Jürgen Pache; Ilka Ott; Jörg Hausleiter; Melchior Seyfarth; Michael Gick; David Antoniucci; Albert Schömig; Peter B Berger; Julinda Mehilli
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Bivalirudin started during emergency transport for primary PCI.

Authors:  Philippe Gabriel Steg; Arnoud van 't Hof; Christian W Hamm; Peter Clemmensen; Frédéric Lapostolle; Pierre Coste; Jurrien Ten Berg; Pierre Van Grunsven; Gerrit Jan Eggink; Lutz Nibbe; Uwe Zeymer; Marco Campo dell' Orto; Holger Nef; Jacob Steinmetz; Louis Soulat; Kurt Huber; Efthymios N Deliargyris; Debra Bernstein; Diana Schuette; Jayne Prats; Tim Clayton; Stuart Pocock; Martial Hamon; Patrick Goldstein
Journal:  N Engl J Med       Date:  2013-10-30       Impact factor: 91.245

3.  Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials.

Authors:  Davide Capodanno; Giuseppe Gargiulo; Piera Capranzano; Roxana Mehran; Corrado Tamburino; Gregg W Stone
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2015-03-06

4.  Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.

Authors:  Matthew A Cavender; Marc S Sabatine
Journal:  Lancet       Date:  2014-08-16       Impact factor: 79.321

5.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Authors:  Yaling Han; Jincheng Guo; Yang Zheng; Hongyun Zang; Xi Su; Yu Wang; Shaoliang Chen; Tiemin Jiang; Ping Yang; Jiyan Chen; Dongju Jiang; Quanmin Jing; Zhenyang Liang; Haiwei Liu; Xin Zhao; Jing Li; Yi Li; Bo Xu; Gregg W Stone
Journal:  JAMA       Date:  2015-04-07       Impact factor: 56.272

6.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

Authors:  Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables
Journal:  Lancet       Date:  2014-07-04       Impact factor: 79.321

7.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský
Journal:  Eur Heart J       Date:  2018-01-07       Impact factor: 29.983

8.  Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).

Authors:  Michel R Le May; George A Wells; Chris A Glover; Derek Y So; Michael Froeschl; Jean-François Marquis; Edward R O'Brien; Michele Turek; Allyson Thomas; Malek Kass; Sachin Jadhav; Marino Labinaz
Journal:  Circ Cardiovasc Interv       Date:  2009-07-22       Impact factor: 6.546

9.  Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.

Authors:  Anthony A Bavry; Islam Y Elgendy; Ahmed Mahmoud; Manoj P Jadhav; Tianyao Huo
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

10.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).

Authors:  Marco Roffi; Carlo Patrono; Jean-Philippe Collet; Christian Mueller; Marco Valgimigli; Felicita Andreotti; Jeroen J Bax; Michael A Borger; Carlos Brotons; Derek P Chew; Baris Gencer; Gerd Hasenfuss; Keld Kjeldsen; Patrizio Lancellotti; Ulf Landmesser; Julinda Mehilli; Debabrata Mukherjee; Robert F Storey; Stephan Windecker
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.